So if we got to that point, what would researchers and regulators actually do with that information? How could improved visibility support oversight and accountability?

I think one big way is that in antitrust policy, for instance, what the regulators really care about is how concentrated a market is in its entirety, and that is difficult to ascertain in a world where you don't know who owns what physician practice.

So it may be the case that a hospital or a private equity firm owns six competing dermatology practices in a city, but that is actually not known at the present moment.

And so when they are acquiring one more practice to add to their collection, if we had that data, the antitrust agencies would be able to look at that quickly and show evidence that, look, this is likely to increase prices without any consumer benefits or offsetting consumer benefits, and that would help them win much more easily in any sort of antitrust action against that sort of merger.

So I think that's really the big piece is just if you are able to keep track of cumulative acquisitions that happen like that, that is a big piece.

And then on the researcher side, I think it is just as a researcher who has tried to track private equity ownership and other corporate ownership in healthcare, it is a morass.

It is very difficult.

And then finally, given all of that, how much appetite do you think there is for increased regulation of corporate activity in healthcare these days? What kinds of policies might be successful in the current political environment?